Trind leads an investment round in Evogenom, a genetic insights company, to enhance its product offerings and support international expansion in the growing health sector.

Target Company Information

Evogenom is a pioneering company in the realm of genetic insights, offering science-based advice to individuals keen on enhancing their overall well-being. Through its innovative mobile application, clients can access personalized genetic analysis after completing an at-home genetic test that they return to the company. Evogenom has distinguished itself in the market by developing proprietary genotyping chips and software that enable a thorough examination of genetic traits.

Under the leadership of CEO Hannu Tolvanen, Evogenom emphasizes its commitment to transforming genetic testing into a user-friendly experience. The company’s advanced genetic tests yield significant insights into aspects such as well-being, recovery, sleep, exercise, nutrition, and medication, making personal health information both accessible and comprehensible to a broad audience.

Industry Overview in the Target's Country

The genetic testing market is currently experiencing rapid growth, driven by an increasing consumer focus on health and wellness. As more individuals seek to understand their genetic makeup to improve lifestyle choi